Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience.

Abstract

Novel, effective therapies are needed for peripheral T-cell non-Hodgkin's lymphoma (PTCL). We treated 16 patients with a combination of gemcitabine, cisplatin and methylprednisolone (GEM-P). Three patients (19%) achieved a complete remission and eight (50%) a partial remission. GEM-P has encouraging efficacy with an acceptable toxicity profile in patients with PTCL.

• Authors: Hendrik-Tobias Arkenau, Geoff Chong, David Cunningham, David Watkins, Bhawna Sirohi, Ian Chau, Andrew Wotherspoon, Andy Norman, Alan Horwich, Estella Matutes
• Journal: Haematologica (Haematologica) Vol. 92 Issue 2 Pg. 271-2 (Feb 2007) ISSN: 1592-8721 [Electronic] Italy
• PMID: 17296587 (Publication Type: Letter)

Chemical References

• Deoxycytidine
• Cisplatin
• Methylprednisolone
• Gemcitabine

Topics

• Adolescent
• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Cisplatin (administration & dosage)
• Deoxycytidine (administration & dosage, analogs & derivatives)
• Female
• Humans
• Lymphoma, T-Cell, Peripheral (drug therapy)
• Male
• Methylprednisolone (administration & dosage)
• Middle Aged
• Prognosis
• Remission Induction
• Treatment Outcome
• Gemcitabine